{"nctId":"NCT01236365","briefTitle":"Statins in Children With Type 1 Diabetes and Hypercholesterolemia","startDateStruct":{"date":"2010-10"},"conditions":["Diabetes Mellitus, Insulin-Dependent","Hypercholesterolemia"],"count":42,"armGroups":[{"label":"Atorvastatin","type":"EXPERIMENTAL","interventionNames":["Drug: Atorvastatin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Atorvastatin Placebo"]}],"interventions":[{"name":"Atorvastatin","otherNames":["Lipitor"]},{"name":"Atorvastatin Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:Project 1\n\n* T1DM diagnosed clinically for \\> 1 year\n* any HbA1C\n* on stable insulin therapy\n* Ages: 10 - 20 years\n* both genders\n* BMI \\< 85th percentile\n* Fasting LDL-C\\>100mg/dl\n* Normal thyroid function\n\nInclusion Criteria:Projects 2 and 3\n\n* T1DM diagnosed clinically for \\> 3 year\n* HbA1C \\> 8%\n* on stable insulin therapy\n* Ages: 12- 20 years\n* both genders\n* BMI \\< 85th percentile\n* Fasting LDL-C\\>100mg/dl\n* Normal thyroid function\n\nExclusion Criteria:Projects 1,2 and 3\n\n* Severe dyslipidemia (LDL-C \\>160, TG \\> 400 mg/dl)\n* Smoking\n* Pregnancy\n* Current use of anti-inflammatory or immunomodulatory drugs, lipid lowering, antidiabetic drugs\n* Patients with hypertension and/or microalbuminuria will be allowed using balanced randomization and standardized treatment","healthyVolunteers":true,"sex":"ALL","minimumAge":"10 Years","maximumAge":"20 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"LDL-C Levels Assessed at Randomization and 6 Months","description":"To assess if the use of statins in children with type 1 DM is safe, improves measures of LDL-C. Subjects will have a physical exam, laboratories, nutritional counseling and moderate aerobic exercise recommended. Diabetes management will be intensified. At 3 months fasting lipoprotein fractions (ion mobility)re-drawn and if LDL-C \\>100mg/dl patients will be randomized to treatment with statins or placebo for 6 months, randomization stratified by BP and microalbuminuria, duration of diabetes and HgA1C. At 1 month safety labs will be repeated and blood withdrawn again at 3 and 6 months from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":"4"},{"groupId":"OG001","value":"87","spread":"5"},{"groupId":"OG002","value":"126","spread":"5"},{"groupId":"OG003","value":"133","spread":"8"}]}]}]},{"type":"PRIMARY","title":"Hs-CRP Levels Assessed at Randomization and 6 Months","description":"To assess if the use of statins in children with type 1 DM decreases the concentration of inflammatory markers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.363","spread":null},{"groupId":"OG001","value":"0.419","spread":null},{"groupId":"OG002","value":"0.248","spread":null},{"groupId":"OG003","value":"0.446","spread":null}]}]}]},{"type":"SECONDARY","title":"MAGE","description":"Mean amplitude of glycemic excursion (MAGE) with continuous glucose monitoring (CGM - IProÂ®, Medtronic Minimed) worn blindly for 6d to assess glucose variability","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":"9"},{"groupId":"OG001","value":"156","spread":"13"},{"groupId":"OG002","value":"156","spread":"6"},{"groupId":"OG003","value":"152","spread":"8"}]}]}]},{"type":"SECONDARY","title":"RAGE","description":"Receptor for Advanced Glycation End Products","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":"11"},{"groupId":"OG001","value":"35","spread":"5"},{"groupId":"OG002","value":"50","spread":"7"},{"groupId":"OG003","value":"58","spread":"17"}]}]}]},{"type":"SECONDARY","title":"Descending Aortic Strain","description":"Subclinical atherosclerosis and arterial stiffness of abdominal aortic MRI","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":"6.4"},{"groupId":"OG001","value":"29","spread":"8.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":21},"commonTop":["Stomach Discomfort","Lower Extremity Cramping","Sinus Symptoms","Cut/Laceration","Rash"]}}}